Stock CGEM CONSOLIDATED GEMS, INC.
Add to a list
To use this feature you must be a member
Log inSign up

News Consolidated Gems, Inc.

Equities

CGEM

US2092631025

Delayed OTC Markets
Other stock markets
 		5-day change 1st Jan Change
- USD -.--% Intraday chart for Consolidated Gems, Inc. -.--% -.--%
Apr. 17 BTIG Adjusts Price Target on Cullinan Oncology to $30 From $20, Maintains Buy Rating MT
Apr. 16 HC Wainwright Cuts Cullinan Oncology's Price Target to $29 From $34, Maintains Buy Rating MT

Summary

Search
See the results
Unlock all the news on all businesses: Never miss an investment opportunity again!
100% Free Registration
BTIG Adjusts Price Target on Cullinan Oncology to $30 From $20, Maintains Buy Rating
MT
HC Wainwright Cuts Cullinan Oncology's Price Target to $29 From $34, Maintains Buy Rating
MT
Wedbush Raises Cullinan Oncology Price Target to $36 From $30, Maintains Outperform Rating
MT
William Blair Initiates Cullinan Oncology With Outperform Rating
MT
Cullinan Oncology Finance Chief Jeffrey Trigilio to Leave
MT
Cullinan Oncology Secures FDA Approval for CLN-619's Investigational New Drug Application in Multiple Myeloma
MT
Wedbush Starts Cullinan Oncology With Outperform Rating, $30 Price Target
MT
Cullinan Oncology Insider Sold Shares Worth $647,200, According to a Recent SEC Filing
MT
Cullinan Oncology Insider Sold Shares Worth $563,600, According to a Recent SEC Filing
MT
Cullinan Oncology Doses First Patient in Study of Advanced Solid Tumor Treatment Candidate
MT
JonesTrading Initiates Cullinan Oncology With Buy Rating, Price Target is $22
MT
TD Cowen Starts Cullinan Oncology at Outperform
MT
Insider Sell: Cullinan Oncology
MT
HC Wainwright Adjusts Price Target on Cullinan Oncology to $49 From $50, Maintains Buy Rating
MT
Cullinan Oncology Gets FDA Clearance for CLN-617 Study
MT
Cullinan Oncology's Q4 Loss Narrows
MT
Cullinan Oncology to Pay $25 Million for License Agreement With Harbour BioMed
MT
Morgan Stanley Adjusts Price Target on Cullinan Oncology to $19 From $27, Maintains Overweight Rating
MT
Cullinan Oncology Says US FDA Approves Investigational New Drug Application for CLN-978
MT
BTIG Initiates Cullinan Oncology With Buy Rating, Sets Price Target at $20
MT
No results for this search
All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Filters

Search

Announcement Date

Since

Until

  1. Stock Market
  2. Equities
  3. CGEM Stock
  4. News Consolidated Gems, Inc.